Pfizer, Inc. · NYSE:PFE
Pfizer — Investor Day (December 2022)
153 slides from Pfizer's investor day presentation, Dec 12, 2022
Slide 1: Near-Term Launches High-Value Pipeline Day
Near-Term Launches High-Value Pipeline Day Christopher Stevo Senior Vice President, Chief Investor Relations Officer December 12, 2022 1
Slide 2: Forward-Looking Statements, Non-GAAP Financial Information and Other Notices
FLS Forward-Looking Statements, Non-GAAP Financial Information and Other Notices Our discussions during Near-Term Launches + High-Value Pipeline Day includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from t
Slide 3: Agenda
AGENDA Agenda Session 1 – Key Near-Term Launches (1-3:30pm) Session 2 – High-Value Pipeline (4-6pm) Welcome – Chris Stevo Pipeline Presentations: Opening Remarks – Angela Hwang • Anti-IFN-β – Mike Corbo and Andy Schmeltz • Danuglipron & PF-1532 – Jim Rusnak and Andy Schmeltz Potential Product Launch
Slide 4: Near-Term Launches High-Value Pipeline Day
Near-Term Launches High-Value Pipeline Day Angela Hwang Chief Commercial Officer President, Global Biopharmaceuticals Business December 12, 2022 Breakthroughs that change patients’ lives ® 4
Slide 5: Fortifying our Long-Term Growth Plans
Introduction Fortifying our Long-Term Growth Plans Illustrative* 2025-2030 Projections ~$20B4 At least $25B3 ~$17B2 2025 Baseline 2025-2030 New BD Deal 2030 2022 YTD & Next 18 Additional Internal 2030 Revenues Revenues1 LOEs Risk-Adjusted Months’ Launches Pipeline Revenue Revenues 2030 Revenues thro
Slide 6: New Launches / Co-promotions and Potential Product Launches
Introduction New Launches / Co-promotions and Potential Product Launches1 Product Candidate Anticipated Indication Expected Launch New Molecular Entity (NME) Launches Ngenla (Ex-US) Growth Hormone Deficiency 2022 Ritlecitinib Alopecia Areata 2023 Elranatamab Triple Class Relapsed or Refractory (Resi
Slide 7: Data & Analytics Designed to Deliver a Superior Omnichannel Customer Experience
Introduction Data & Analytics Designed to Deliver a Superior Omnichannel Customer Experience Our customers expect a seamless experience that is more personalized, scientifically robust, and efficient in addressing patient needs. A Personalized Experience High Tech Relevant Engagements An Expert Reso
Slide 8: Evolving an Enhanced Customer Experience at Speed and Scale
Introduction Evolving an Enhanced Customer Experience at Speed and Scale Redefined Our Go-To-Market Model to Transform How We Engage with HCPs and Patients 68 80+ 16,000+ 2,500+ Markets now live with the New Data Scientists and Customer Facing roles New Subject Matter new organizational model a new
Slide 9: Driving Commercial Excellence – Biopharma's Operating Model Evolution
Introduction Driving Commercial Excellence – Biopharma’s Operating Model Evolution 3 Global Customer-Focused Organizations Angela Lukin Kevin Sullivan Suneet Varma Business President Business President Business President Global Global Global Primary Care Specialty Care Oncology (COVID, Vaccines, Int
Slide 10: Resources, Capabilities & Track Record of Leadership
Resources, Capabilities & Track Record of Leadership Introduction Commercial and Manufacturing Leadership Industry Leadership • For the 3rd year in a row, Pfizer’s sales forces have ranked #1 across Core • Pfizer ranked #1 for the first time ever in the 2021 Patient View Global Specialties, which in
Slide 11: New Launches / Co-promotions and Potential Product Launches
Introduction New Launches / Co-promotions and Potential Product Launches1 Primary Care Specialty Care Oncology 2022 2023 2023 • Nurtec ODT/Vydura • Ritlecitinib • Elranatamab 2023 • Etrasimod • Talzenna (Talazoparib) + Xtandi (enzalutamide) • RSV Adults (60+) • RSV Maternal 1 Over the next 18 months
Slide 12: Nurtec ODT/Vydura and zavegepant (BHV-3500)
Nurtec® ODT/Vydura® and zavegepant (BHV-3500) Potential Breakthrough Therapies for Patients with Migraine Rodrigo Puga US Commercial & Global Business Lead Internal Medicine December 12, 2022 12
Slide 13: Disease Overview & Demographics: Migraine
Migraine Disease Overview & Demographics: Migraine Migraine is a Debilitating Disease Impacting Over 1B Patients Worldwide Migraine is a life disrupting disease and has a negative impact ranging from lost productivity at work to repercussions on relationships and parenting1 Migraine is a common neur
Slide 14: Understanding Migraine Disease & Treatment Approaches
Migraine Understanding Migraine Disease & Treatment Approaches Type of Episodic Chronic Migraine1,2 Migraine Migraine Headache Days Per Month1,2,3 ≤14 Days 15+ Days % of Patients3 94% 6% Treatment Acute Treatment Approach2,4 Preventive Treatment Source: 1. https://www.ichd-3.org/1-migraine/. 2. Aila
Slide 15: Migraine Unmet Needs Span both Acute and Preventive Treatment
Migraine Migraine Unmet Needs Span both Acute and Preventive Treatment Patients With Migraine Have Struggled With The Limitations of Migraine treatments Potential Limitations: Acute Treatment1−5 Potential Limitations: Preventive Care6−12 Medication Need for Rescue Route of Delayed Overuse Medication
Slide 16: Nurtec ODT/Vydura Can Help Address Many Unmet Needs
Migraine Nurtec® ODT/Vydura® Can Help Address Many Unmet Needs Associated with Acute and Preventive Therapy Acute Treatment – Nurtec/Vydura Preventive Treatment – Nurtec/Vydura Patients starting anti-CGRP therapy Low Need for 86% of patients had no need for Oral Versus have expressed a preference fo
Slide 17: Nurtec ODT/Vydura Changes the Treatment Paradigm
Nurtec® ODT/Vydura® Changes the Treatment Paradigm ACUTE PREVENTIVE Treatment Treatment lasmiditan atogepant triptans erenumab ubrogepant fremanezumab galcanezumab SOC* incl. topiramate Source: Reyvow USPI, Ubrelvy USPI, Nurtec USPI, Eigenbrodt AK et al, Nature Reviews – Neurology, Source: Vyepti US
Slide 18: Nurtec ODT/Vydura Provides Flexibility to Patients and Physicians
Migraine Nurtec® ODT/Vydura® Provides Flexibility to Patients and Physicians Nurtec ODT/Vydura is the First And Only Medication Approved For The Acute Treatment of Migraine and Preventive Treatment of Episodic Migraine in Adults1 Achieved Pain Freedom Provides Sustained Pain Reduces Monthly Establis
Slide 19: Nurtec ODT Performance Highlights in the U.S. Market
Migraine Nurtec® ODT Performance Highlights in the U.S. Market Since Launch, Nurtec ODT Continues To Show Robust Growth Total Rx Volume - Oral CGRPs (11/18)1 50.7% TRx Share >600,000 +6.4% Pt Increase Unique Patients Since Launch from May-Nov 20221 in February 20202 >90K HCPs 11/18 Unique Prescriber
Slide 20: High Growth Potential Within A Rapidly Growing Market
Migraine High Growth Potential Within A Rapidly Growing Market US Migraine Market Is Expected to Grow to ~40+ Million Scripts; Oral CGRPs are the Fastest Growing Class TRx Share1 Quarterly TRx Volume Oral CGRPs vs Triptans + Topiramate¹ 1,089,374 Oral CGRPs3 2,974,224 Topiramate 16% 3,942,413 Tripta
Slide 21: Building a Franchise to Potentially Meet the Needs of People with Migraine
Migraine Building a Franchise to Potentially Meet the Needs of People with Migraine Nurtec® ODT/Vydura® Is Well-Positioned for Leadership, with zavegepant* Potentially Bringing the Opportunity for Portfolio Play Type of Migraine (Headache Days Episodic (≤14) Chronic (15+) Per Month) 1, 2, 3 Acute Tr
Slide 22: A Closer Look at Key Drivers of Potential Migraine Revenues
Migraine A Closer Look at Key Drivers of Potential Migraine Revenues Significant Potential to Build a Blockbuster Migraine Portfolio Nurtec® ODT/Vydura® zavegepant Intranasal* zavegepant Oral Indication Acute Treatment Episodic Prevention Acute Treatment Chronic Prevention Migraine Population US Dia
Slide 23: Commercial Strategy: Amplifying the Migraine Portfolio
Migraine Commercial Strategy: Amplifying the Migraine Portfolio Success in 2023 & Beyond Will Be Driven By Current Momentum and Expanding Reach Across the Globe Expand customer base to include 250+ US health systems with leading account management; provide 8x more field medical support Continue mome
Slide 24: Pfizer Is Well-Positioned to Become a Leader in Migraine
Migraine Pfizer Is Well-Positioned to Become a Leader in Migraine Growth Trajectory to Potential $6B Peak Year Sales for Nurtec® ODT/Vydura® and zavegepant worldwide (est.) Launch Globally …and moving at lightspeed to launch across the globe Expand in US We are taking Nurtec ODT to Migraine the next
Slide 25: Respiratory Syncytial Virus (RSV) PreF Vaccine Candidate
Respiratory Syncytial Virus (RSV) PreF Vaccine Candidate Sinan Atlig US Commercial and Global Business Lead for Vaccines December 12, 2022 25
Slide 26: Disease Overview & Demographics: Respiratory Syncytial Virus (RSV)
RSV Disease Overview & Demographics: Respiratory Syncytial Virus (RSV) Contagious Virus That Can Cause Serious, Sometimes Life Threatening, Respiratory Illness RSV in Infants • A leading cause of global infant respiratory disease1,2 • Sickens ~6.6M infants resulting in ~45K deaths globally each year
Slide 27: Pfizer's RSVpreF Vaccine Candidate – Overview
RSV Pfizer’s RSVpreF Vaccine Candidate – Overview Vaccine Bivalent stabilized prefusion F • Sequence based on contemporary RSV A and RSV B strains • Elicited high neutralizing titers for both RSV A and RSV B in Phase 1/2 studies1,2,3 • No adjuvant or viral vector component Only RSV Vaccine Candidate
Slide 28: RSV Older Adult: BLA Granted Priority Review with Potential PDUFA May 2023
RSV RSV Older Adult: BLA Granted Priority Review with Potential PDUFA May 2023 Phase 3 RENOIR Study Interim Analysis Systemic Events, by Maximum Severity, Within 7 Days After Vaccination Efficacy Outcome (1 Season) 40 100 Higher RSV acute respiratory illness Muscle efficacy (ARI)1 62% 35 Any Fatigue
Slide 29: RSV Maternal Immunization: Help Protect Infants from Severe RSV
RSV RSV Maternal Immunization: Help Protect Infants from Severe RSV* Immediately at Birth Phase 3 MATISSE Study Interim Analysis Primary Endpoint: Severe MA-LRTI Primary Endpoint: MA-LRTI Vaccine Efficacy Vaccine Efficacy 81.8% 57.1% First 90 days of life First 90 days of life (CI: 40.6%, 96.3%) (CI
Slide 30: Commercialization Approach: Pfizer Vaccines Commercial Leadership
RSV Commercialization Approach: Pfizer Vaccines Commercial Leadership Decades of Vaccines Launch Excellence Robust and Longstanding and Deep Proven and Reliable Leading Share Differentiated Relationships with Manufacturing of Voice Among Contracting Models Key Stakeholders and Distribution Consumers
Slide 31: RSV Vaccine Candidate: Potential Revenues More Than $2Bn
RSV RSV Vaccine Candidate: Potential Revenues More Than $2Bn Key Drivers of Potential RSV Vaccine Revenues (Internal Assumptions - US) Maternal Immunization Older Adults Population (US) 3.5-4 Million (annual birth cohort) • ~61 Million (>65 yrs) • New aged-in cohort ~3.5-4 Million annually Peak Vacc
Slide 32: Pfizer's Respiratory Portfolio: Strong Legacy, Future Potential
RSV Pfizer’s Respiratory Portfolio: Strong Legacy, Future Potential Today Today Tomorrow (potential) Pneumococcal Pneumonia RSV RSVPreF* Sisunatovir*† (Treatment) Influenza mRNA Flu*† COVID-19 1 Potential Combination Vaccine Candidates (Treatment) mRNA Flu / Potential additional combination COVID*†
Slide 33: Etrasimod
Etrasimod Ulcerative Colitis (UC) Kevin Sullivan Global Specialty Care & US President December 12, 2022 Breakthroughs that change patients’ lives® 33
Slide 34: Disease Overview & Demographics: Ulcerative Colitis
Etrasimod UC Disease Overview & Demographics: Ulcerative Colitis “A UC diagnosis is a life sentence that wreaks havoc on the body. It turns any day to chaos in an instant.”1 Ulcerative Colitis (UC) is a chronic and often debilitating inflammatory bowel disease that affects an estimated 1 million peo
Slide 35: The UC Patient Experience
Etrasimod UC The UC Patient Experience UC is a Debilitating Disease That is Difficult for Those Not Suffering to Understand You never know when it's going to strike you and I mean that sincerely; you can have plans and they get messed up because you have a bout. It's not only the physical feeling of
Slide 36: Current Treatment Landscape: Ulcerative Colitis
Etrasimod UC Current Treatment Landscape: Ulcerative Colitis Majority of UC Patients are on Conventional Therapies and Many Struggle to Achieve and Maintain Remission UC Treated Patients – New to Tx & Already on Tx1 52% Of UC patients on AT don't All UC Patients: Mild, Moderate & Severe Dx retain lo
Slide 37: Significant Potential Remains for Oral Therapies in 1L Advanced Tx
Etrasimod UC Significant Potential Remains for Oral Therapies in 1L Advanced Tx (AT) Given Current SOC Options, Movement into 1L AT Today Often Means Movement Away from Patient Preferred Oral Therapy1 Pre-Arrival of S1Ps: UC Treatment Paradigm Cyclosporine / Tacrolimus / Surgery 89% Of advanced naïv
Slide 38: Etrasimod Overview: The Next S1P With a High Potential Emerging Profile
Etrasimod UC Etrasimod* Overview: The Next S1P With a High Potential Emerging Profile If Approved, a New S1P with High Potential to Become the Preferred 1L Advanced Treatment (AT) Option by Balancing a Favorable Benefit:Risk Profile and Oral Administration Key Potential Differentiators ELEVATE UC 12
Slide 39: Ulcerative Colitis Marketed Tx Competitive Landscape
Etrasimod UC Ulcerative Colitis Marketed Tx Competitive Landscape For Advanced-Naïve Patients, HCP’s Top Prescribing Considerations Span Product Attributes & Company / Brand Perceptions UC Treatment Landscape: Marketed MOAs – Past / Pre-Arrival of S1Ps HCP Reported Top Drivers of Prescribing TNFi An
Slide 40: Ulcerative Colitis Marketed Tx Competitive Landscape
Etrasimod UC Ulcerative Colitis Marketed Tx Competitive Landscape <3% Of patients receiving Arrival of the S1P Class to IBD (2021) Provided the return of an oral Tx today in 1st Oral Option for 1L Advanced Tx Patients Line4 UC Treatment Landscape: Marketed MOAs – Current / Post-Arrival of S1Ps HCP R
Slide 41: Commercialization Approach: Etrasimod's Potential Future Opportunity
Etrasimod UC Commercialization Approach: Etrasimod’s Potential Future Opportunity Potential to Redefine the Treatment Paradigm in 1L Advanced Tx, if Approved Safety profile supports potential 1 in 3 patients enrolled in clinical Benefit: Risk profile supports for no boxed warning* remission after 1
Slide 42: I&I Category and Specialty Care Commercialization Expertise
Etrasimod UC I&I Category and Specialty Care Commercialization Expertise Providing an Advanced Therapy Portfolio for Moderate-to-Severe UC Patients* UC Therapeutic Accelerating Potentially Raising Portfolio Global Access the Standard of Caring for IBD Patients Etrasimod* >50% Goal to become the pref
Slide 43: Etrasimod UC Market Potential
Etrasimod UC Etrasimod UC Market Potential Blockbuster Potential Global Annual Peak Revenues Etrasimod in Ulcerative Colitis (UC) 1.7M+ UC Dx prevalence in top 5 developed markets1 80% Rx treated patients2 Up to 35% Advanced treated patients3 50% Expected market growth in next 5 years4 $1-2B Global
Slide 44: Ritlecitinib
Ritlecitinib Alopecia Areata (AA) Kevin Sullivan Global Specialty Care & US President December 12, 2022 Breakthroughs that change patients’ lives® 44
Slide 45: Disease Overview and Demographics: Alopecia Areata (AA)
Ritlecitinib AA Disease Overview and Demographics: Alopecia Areata (AA) AA Can Affect Up to 2% of the Global Population Over the Course of Their Lifetime1-4,10 AA is an Autoimmune Disease Characterized by Age9-11 Patchy or Complete Hair Loss on the Scalp, Face and or Body5-9 AA can affect all ages a
Slide 46: The Alopecia Areata Patient Experience
Ritlecitinib AA The Alopecia Areata Patient Experience AA Can Cause Considerable Burden for Patients, Beyond Hair Loss1-5 Studies of Adults and Adolescents Have Shown6,7: [Every day] since I found that of patients report that coping with first patch…[I have thought] 85% Alopecia Areata is a daily ch
Slide 47: Current Treatment Landscape: Alopecia Areata
Ritlecitinib AA Current Treatment Landscape: Alopecia Areata High Level of Dissatisfaction with Standard of Care (e.g., Topical and Intralesional Steroids) Initial Hair Loss HCP Presentation Oral Topical/Intralesional Steroids & Self Treatment & Diagnosis Treatments Current standard of care has Oral
Slide 48: Ritlecitinib Overview in Alopecia Areata
Ritlecitinib AA Ritlecitinib Overview in Alopecia Areata Robust Clinical Data Support Transformative Potential Clinical Results ALLEGRO-2b/3 Clinical Photos ALLEGRO 2b/3 50 SALT ≤20 Week 24 Ritlecitinib 50 mg QD Ritlecitinib 30 mg QD Baseline Week 24 Week 48 Placebo Proportion (%) of participants 40
Slide 49: Commercialization Approach: Ritlecitinib's Potential Future Opportunity
Ritlecitinib AA Commercialization Approach: Ritlecitinib’s* Potential Future Opportunity Potential to Redefine the Standard of Care in Alopecia Areata* First and only dual-selective TEC Data on complete Favorable family/JAK3 inhibitor; or near-complete scalp benefit/risk profile sparing inhibition o
Slide 50: Medical Dermatology and Specialty Care Commercialization Expertise
Ritlecitinib AA Medical Dermatology and Specialty Care Commercialization Expertise Poised for a Potential Best-in-class Launch Develop the Market Unlock Access Drive Adoption1 • Pre-launch omnichannel • Advocate for adequate AA • Industry-leading capabilities approach providing unbranded coverage an
Slide 51: Ritlecitinib Alopecia Areata Market Potential
Ritlecitinib AA Ritlecitinib Alopecia Areata Market Potential Blockbuster Potential Global Annual Peak Revenues Ritlecitinib in AA 6.4M Adult AA prevalence(1) 43% ≥ 50% scalp hair loss(2) 28–49% Diagnosed and seeing a Dermatologist(3) 38–46% Candidates for advanced treatment(4) ~$1B Global revenue p
Slide 52: Elranatamab
Elranatamab Potential to Bring Transformative Outcomes to More Patients in Multiple Myeloma Suneet Varma Global Oncology & US President December 12, 2022 52
Slide 53: Disease Overview & Demographics: Multiple Myeloma (MM)
Elranatamab Disease Overview & Demographics: Multiple Myeloma (MM) MM is the Second Most Common Despite Advances That Have Improved Survival, MM Remains Hematologic Malignancy Worldwide1 Incurable, With Most Patients Progressing to RRMM5 Each relapse for patients with MM results in6,7: 13% ~1% Highe
Slide 54: BCMA-Targeted Treatments in Relapsed or Refractory Multiple Myeloma
Elranatamab BCMA-Targeted Treatments in Relapsed or Refractory Multiple Myeloma BCMA Bispecific Antibodies (BsAbs) have potential to be the preferred modality for treating Multiple Myeloma, promising efficacy and broad availability Elranatamab Bispecific Antibody Mechanism HCP Perceptions of BCMA-Di
Slide 55: Elranatamab Overview: Evaluated in a Broad, Heavily Pre-treated Patient Population
Elranatamab Elranatamab Overview: Evaluated in a Broad, Heavily Pre-treated Patient Population, Representative of Those with Highest Unmet Need MagnetisMM-31 Patient Population (n=187) Real World TCE Population2 1 in 2 1 in 6 Prior Prior BCMA BCMA ~ ~ 45.5% 39.6% 34.2% 17.7% 13.3% 2.8% (85) (74) (64
Slide 56: Elranatamab: Opportunity to Be a Leader in the BCMA BsAb Class
Elranatamab Elranatamab: Opportunity to Be a Leader in the BCMA BsAb Class Transformative Potential in an Area of High Unmet Need MagnetisMM-3 Data Presented at ASH 2022 (Dec. 10, 2022) Ph2: Cohort A (n=123) non-BCMA Exposed, 10.4 Mos Follow Up (October 14, 2022 Cut Off) Early and Deep Responses Man
Slide 57: Elranatamab Market Potential: Patient Impact Expected to Build Over Time
Elranatamab Elranatamab Market Potential: Patient Impact Expected to Build Over Time BCMA BsAb Class Potential to Capture 40%-80% Market Share, with Elranatamab 1st or 2nd in Class Total Addressable Patient Population MagnetisMM-6: $4B+ Ph3 Potential Peak Revenue MagnetisMM-7: Ph3 MagnetisMM-5: Ph3
Slide 58: Talzenna
Talzenna Prostate Cancer (PC) Suneet Varma Global Oncology & US President December 12, 2022 58
Slide 59: Disease Overview & Demographics: Prostate Cancer (PC)
Talzenna in Prostate Cancer Disease Overview & Demographics: Prostate Cancer (PC) 2nd Most Common Cancer in Men and 5th Most Common Cause of Death in Men Worldwide1. Metastatic Prostate Cancer is Associated with a Relative 5-year Survival Rate of Only 31%2 Worldwide U.S. ~1.4 million new cases of ~2
Slide 60: Disease Progression to mCRPC is Associated with Poor Outcomes
Talzenna in Prostate Cancer Disease Progression to mCRPC is Associated with Poor Outcomes Prostate Cancer Disease Continuum: How the Disease Progresses 2028 G7 Projected Treatment-eligible Patients and Projected Therapeutic Market Size1,2 1. Kantar modified epidemiology 2. Clarivate Decision Resourc
Slide 61: Talzenna PC Overview: TALAPRO-2 and XTANDI in mCRPC
Talzenna in Prostate Cancer Talzenna PC Overview: TALAPRO-2 is the First PARPi Combined with XTANDI to Demonstrate Clinical Benefit in mCRPC Patients with or without HRR Gene Mutations • Achieved primary endpoint with statistically significant Phase 3 study of TALZENNA® and clinically meaningful imp
Slide 62: TALAPRO-2 Demonstrates Compelling Data on the Use of PARPi + ARi Upfront
Talzenna in Prostate Cancer TALAPRO-2 Demonstrates Compelling Data on the Use of PARPi + ARi Upfront Regardless of HRR Mutational Status Potential Synergistic Impact Potentially 1st Combination to 1L mCRPC All-comers Efficacy of PARPi + ARi Combination Market with XTANDI ARi Backbone* with Potential
Slide 63: TALAPRO-2 Combination Expected to Compete with PROpel Combination
Talzenna in Prostate Cancer We Expect the TALAPRO-2 Combination to Compete with PROpel Combination in All-comers 1st Line mCRPC, if Approved1, 2 PROpel MAGNITUDE TALAPRO-2 Olaparib + abiraterone Niraparib + abiraterone Talazoparib + enzalutamide (1) DDR positive (n=423) (1) All-comers Study Populati
Slide 64: Talzenna PC Market Potential
Talzenna in Talzenna PC Market Potential Prostate Cancer PARP Inhibitor + NHT Combinations are Uniquely Positioned to Drive Market Growth in Advanced Prostate Cancer Large, Growing Advanced Prostate Cancer $1B+ 1st Line Peak Year mCRPC Therapeutics G7 Market Projected to Reach Potential Peak Assumpt
Slide 65: Q&A Key Near-Term Launches
Q&A Key Near-Term Launches 65
Slide 66: Near-Term Launches High-Value Pipeline Day
Near-Term Launches High-Value Pipeline Day Andy Schmeltz SVP, Commercial Strategy & Innovation December 12, 2022 Breakthroughs that change patients’ lives ® 66
Slide 67: Forward-Looking Statements, Non-GAAP Financial Information and Other Notices
FLS Forward-Looking Statements, Non-GAAP Financial Information and Other Notices Our discussions during Near-Term Launches + High-Value Pipeline Day includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from t
Slide 68: Fortifying our Long-Term Growth Plans
Introduction Fortifying our Long-Term Growth Plans Illustrative* 2025-2030 Projections Focus of this discussion ~$20B4 At least $25B3 ~$17B2 2025 Baseline 2025-2030 New BD Deal 2030 2022 YTD & Next 18 Additional Internal 2030 Revenues Revenues1 LOEs Risk-Adjusted Months’ Launches Pipeline Revenue Re
Slide 69: Today We Will Focus On Select High-Value Programs in Our Robust Pipeline
Introduction Today We Will Focus On Select High-Value Programs in Our Robust Pipeline1 Inflammation & Internal Rare Hospital Oncology Vaccines Immunology Medicine Disease (Anti-Infectives) Ritlecitinib Zavegepant (intranasal) Sasanlimab + Bacillus Calmette-Guerin Somatrogon BNT162b2 bivalent (BA.4/B
Slide 70: High-Value Pipeline Section Agenda
Introduction High-Value Pipeline Section Agenda Pipeline Presentations Speakers Mike Corbo, Chief Development Officer, Inflammation & Immunology Anti-Interferon-beta (IFN-β) Andy Schmeltz, SVP, Commercial Strategy & Innovation Jim Rusnak, Chief Development Officer, Internal Medicine & Hospital Danug
Slide 71: Anti-Interferon-beta (IFN-β) PF-06823859
Anti-Interferon-beta (IFN-β) PF-06823859 A Potential Breakthrough in Dermatomyositis and Polymyositis Mike Corbo SVP, Chief Development Officer, Inflammation & Immunology Andy Schmeltz SVP, Commercial Strategy & Innovation December 12, 2022 71
Slide 72: Disease Overview & Unmet Need: Dermatomyositis (DM)
IFN-β Disease Overview & Unmet Need: Dermatomyositis (DM) A Severely Debilitating and Life-threatening Specialty Rheumatology Indication Severely debilitating & life-threatening disease affecting skin & muscle1 Symptoms: inflammation, malaise, and muscle weakness; severe disease may have fibrotic or
Slide 73: Inhibiting IFN-β is a Promising Novel Approach to Treating Dermatomyositis
IFN-β Inhibiting IFN-β is a Promising Novel Approach to Treating Dermatomyositis Homing in on a Driver of Disease – Interferons: One of Many Immune Modulating Cytokines Cytokines Are Made by Many Cells Reduction in Body Weight After Interferons and Signal Through the Body 12-week Treatment Macrophag
Slide 74: Uncovering a Role for IFN-β in Disease
IFN-β Uncovering a Role for IFN-β in Disease Pfizer CTI Collaboration Explores Potential Treatment Candidate Biology Pfizer CTI Collaboration Delivers Treatment Candidate 1 IFN-β is secreted by fibroblasts • Researchers at Brigham and Women's Fibroblast IFN-β Hospital and Harvard Medical School β β
Slide 75: Anti-IFN-β Breakthrough Potential Based on Successful Phase 2 Study
IFN-β Anti-IFN-β Has Breakthrough Potential for Dermatomyositis Based on a Successful Phase 2 Study Primary Efficacy Endpoint Met: Skin Disease Endpoint Target Value Exceeded Change in Skin Disease Score Responder Rates (%) 0 Change from Baseline -5 Placebo 150 mg 600 mg (N=14) (N=15) (N=15) -10 Ski
Slide 76: Anti-IFN-β Phase 2 Study Also Delivered Promising Data in Muscle Predominant Cohort
IFN-β Anti-IFN-β Phase 2 Study Also Delivered Promising Data in Muscle Predominant Cohort Significant Differences Identified in Patient Reported Outcomes and Improvement Scores Change in Patient Global Assessment (PtGA) Change in Creatine Kinase Muscle Damage Biomarker of Myositis Change from Baseli
Slide 77: Scientific Justification for a Basket Approach
IFN-β Scientific Justification for a Basket Approach Dermatomyositis (DM) & Polymyositis (PM) Overexpress Type 1 Interferons IFN-inducible Genes Are Overexpressed in Both DM & PM Relative to Normal Muscle Biopsies IF127 DM PM Normal G1P3 IF1T2 LY6E OAS2 OAS1 IF144L IF144 OAS3 HERC5 Mx1 CMPK2 IFIT1 R
Slide 78: Moving Anti-IFN-β Forward to Phase 3
IFN-β Moving Anti-IFN-β Forward to Phase 3 Plan to Advance to Pivotal Development Concurrently in Dermatomyositis and Polymyositis Efficacy signal Safety profile: Advance to Team's challenge: observed in no pan-interferon pivotal Can we pursue skin & muscle safety signals development more indication
Slide 79: Disease Overview & Unmet Need: Polymyositis (PM)
IFN-β Disease Overview & Unmet Need: Polymyositis (PM) A Severely Incapacitating Specialty Rheumatology Indication Defined by inflammation of the proximal muscles Symptoms: muscle weakness, typically symmetrical; Difficulty going up stairs, combing hair, and raising one’s arms or head Fever May incl
Slide 80: Market Opportunity: Dermatomyositis (DM) and Polymyositis (PM)
IFN-β Market Opportunity: Dermatomyositis (DM) and Polymyositis (PM) ~ $6-12B Projected Advanced Therapy Category Spanning DM and PM (2030) Potential US Total Addressable DM and PM Opportunity – (2030, Projected) 120-180K1 30-40%2 80% 85% $150K3 ∼$3–6B Prescribed US Opportunity U.S. Patients Market
Slide 81: Commercial Potential: Anti-IFN-β in Dermatomyositis and Polymyositis
IFN-β Commercial Potential: Anti-IFN-β in Dermatomyositis and Polymyositis Opportunity to Potentially Contribute $1-3B in Peak Year Sales All DM/PM Number of diagnosed DM/PM patients projected to grow by up Projected DM/PM Market Therapies to ~50%1 Advanced >Delayed diagnosis and misdiagnosis are co
Slide 82: In Brief: Pfizer's Anti-IFN-β is a Potential Game-Changer for Patients
IFN-β In Brief: Pfizer’s Anti-IFN-β is a Potential Game-Changer for Patients Anti-IFN-β – Potential: A Compelling Value Proposition Target a single pathway to achieve superior efficacy 1. Specialty rheumatology diseases with significant unmet while avoiding pan-interferon safety signals need; few
Slide 83: PF-07081532 & Danuglipron
PF-07081532 & Danuglipron Potentially Best-in-Class Oral GLP-1RA Jim Rusnak SVP, Chief Development Officer, Internal Medicine & Hospital Andy Schmeltz SVP, Commercial Strategy & Innovation December 12, 2022 83
Slide 84: Disease Overview & Unmet Need: Obesity and Type 2 Diabetes
GLP-1 Disease Overview & Unmet Need: Obesity and Type 2 Diabetes Chronic Medical Conditions That Can Lead to Serious CV, Metabolic and Other Health Consequences Rising rates of obesity and diabetes carry significant health consequences Global Obesity Prevalence: 650M1; 1.025B2 projected by 2030 Low
Slide 85: GLP-1 Receptor Agonists Are Well-suited to Tackle Obesity and Type 2 Diabetes
GLP-1 GLP-1 Receptor Agonists Are Well-suited to Tackle Obesity and Type 2 Diabetes Class of Medicines Addresses Key Drivers of These Diseases GLP-1 Receptor Agonists (GLP-1RAs) Decreased Delayed Gastric Increased Insulin Appetite Emptying Secretion GLP-1RAs Shown to Have Effects on Weight Loss, Gly
Slide 86: Pfizer Innovation Delivers Full Agonist Investigational Oral GLP-1RAs
GLP-1 Pfizer Innovation Delivers Full Agonist Investigational Oral GLP-1RAs Potent and Efficacious Small-molecule Agonists of the GLP-1R, Differentiated by Full Agonist Biochemical Profiles Sensitized Screening Assay Development of Two oral compounds with favorable characteristics and distinct sensi
Slide 87: Danuglipron: Potent Glycemic and Weight Loss Efficacy After 12 Weeks in Phase 2a
GLP-1 Danuglipron: Potent Glycemic and Weight Loss Efficacy After 12 Weeks in Phase 2a Dose-dependent Reductions in Both HbA1c and Body Weight in Patients with Type 2 Diabetes Decrease in HbA1c After 12-week Treatment Reduction in Body Weight After 12-week Treatment Placebo Danuglipron 200 mg BID Pl
Slide 88: PF-07081532: A Once-daily Full Agonist with Dose-responsive Reductions
GLP-1 PF-07081532: A Once-daily Full Agonist with Dose-responsive Reductions Dose-dependent Reductions in Both Glucose and Body Weight in Patients with T2D (and Body Weight in Patients with Obesity) After 4-6 Weeks in Phase 1b Decrease from Baseline in Mean Daily Glucose at 4-6 Weeks Reduction in Bo
Slide 89: GLP-1RA Clinical Development Plan
GLP-1 GLP-1RA Clinical Development Plan Plan to Advance One Candidate to Phase 3 (T2D & Obesity) Based on Efficacy, Tolerability and Dosing PF-07081532 Recently Completed Initiated Ongoing Phase 2b Studies Will Evaluate: Phase 2b (32-wk) study Phase 1 (4-6-wk) study (T2D & Obesity) • Higher doses of
Slide 90: Market Opportunity: GLP-1RA
GLP-1 Market Opportunity: GLP-1RA >$90B Projected GLP-1 Total Addressable Market Spanning Type 2 Diabetes and Obesity (2030, Based on Assumptions) GLP-1RA Opportunity – Type 2 Diabetes (2030, Projected) 25-30MM 100% 25-30% 65-70% $15-20 ∼$35-40B U.S. Patients GLP-1 Class Market Size Seeking Reimburs
Slide 91: Danuglipron/PF-07081532 Commercial Potential
GLP-1 Danuglipron/PF-07081532 Commercial Potential Opportunity to Potentially Contribute $10B+ in Peak Year Sales GLP-1RA Class $25B GLP-1 market currently growing at +30% per year, ~$90B projected to reach ~$90B by 2030 Orals projected to capture ~30% of GLP-1 market by 2032 due to strong patient p
Slide 92: In Brief: Pfizer's Oral GLP-1RA Candidates Are Potential Game-changers
GLP-1 In Brief: Pfizer’s Oral GLP-1RA Candidates Are Potential Game-changers Danuglipron and PF-07081532 – Potential to: A Compelling Value Proposition • Deliver potent effects on blood sugar and weight loss 1. GLP-1RAs rapidly emerging as increasingly important • Have safety and tolerability compar
Slide 93: TTI-622
TTI-622 A Potential Backbone Combination Agent for Hematological Malignancies Chris Boshoff SVP, Chief Development Officer, Oncology & Rare Disease Andy Schmeltz SVP, Commercial Strategy & Innovation December 12, 2022 93
Slide 94: Malignant Hematology
TTI-622 Malignant Hematology Worldwide, ~720K People Die from Blood Cancer Each Year, Accounting for >7% of Cancer Deaths1 Heme Malignancies: Multiple myeloma (MM), Diffuse Large B-cell Lymphoma (DLBCL), and Acute Myeloid Leukemia (AML) Incidence1 (2022 – US, EU, JP): MM: ~70K DLBCL: ~75K AML: ~40K
Slide 95: TTI-622 is Emerging as a Potential Best-in-Class CD47 Blocker
TTI-622 TTI-622 is Emerging as a Potential Best-in-Class CD47 Blocker CD47 Delivers an Inhibitory “Don’t Eat Me” Signal to Macrophages Through SIRPα Unlike Anti-CD47 Antibodies, TTI-622 is a SIRPα Decoy Receptor-IgG4 Fc Fusion Protein with Dual Activity • TTI-622 blocks CD47 TTI-622 • Exerts a proph
Slide 96: TTI-622 is Differentiated from Other CD47-blocking Agents
TTI-622 TTI-622 is Differentiated from Other CD47-blocking Agents Preclinical RBC Binding Minimal Human RBCs has Potential for1-3 M e a n F lu o r e s c e n c e In te n s ity 10 6 10 5 • Combination with agents that cause anemia and other 10 4 cytopenias is feasible • Lower amount of drug by avoidin
Slide 97: TTI-622 is the Only CD47 Agent with Monotherapy Activity Including Complete Responses
TTI-622 TTI-622 is the Only CD47 Agent with Monotherapy Activity Including Complete Responses Across Lymphoid Malignancies Target Lesion Change - Phase 11 AE Profile1 100 Evaluable Best Responses (%) • The majority of AEs seen Patients (n) with single agent therapy ≥ 75 CR PR SD OR DCR 34 2 (6) 7 (2
Slide 98: Development Plan: Pursuing Unique and Rational Combinations Across Heme Malignancies
TTI-622 Development Plan: Pursing Unique and Rational Combinations Across Heme Malignancies Stage of Development Combination Indication IND Rationale Agent Preclinical Phase 1/2 Phase 3 Enabling IKd* Engaging innate and adaptive Multiple Myeloma arms of the immune system (MM) Elranatamab (BCMAxCD3)*
Slide 99: Market Opportunity: Sizable and Growing Across Hematologic Malignancies
TTI-622 Market Opportunity: Sizable and Growing Across Hematologic Malignancies Total Current and Potential Accessible Market Worldwide ($B)1 Multiple Diffuse Large B-Cell Acute Myeloid Myeloma (MM) Lymphoma (DLBCL) Leukemia (AML) $ 33 16% CAGR $ 22 $10 15% CAGR $3 5% CAGR $3 $1 2022 2030 2022 2030
Slide 100: Commercial Potential: Position TTI-622 to be a Potential Blockbuster
TTI-622 Commercial Potential: Early Signs of Clinical Efficacy, Combinability, and Differentiated Tolerability Position TTI-622 to be a Potential Blockbuster Multiple Diffuse Large B-Cell Acute Myeloid Myeloma (MM) Lymphoma (DLBCL) Leukemia (AML) 80K 86K 45K 2030 WW Incidence1 2030 WW Incidence1 203
Slide 101: In Brief: TTI-622 is a Potential Game-Changer for Heme Patients
TTI-622 In Brief: TTI-622 is a Potential Game-Changer for Heme Patients TTI-622 – Potential to A Compelling Value Proposition Offer differentiated safety profile 1 TTI-622 has the potential to enter multiple (e.g., anemia risk reduction) lines of therapy in markets of malignant through minimal RBC b
Slide 102: Inclacumab & GBT-601
Inclacumab & GBT-601 Potential Transformative Therapies for Sickle Cell Disease Chris Boshoff SVP, Chief Development Officer, Oncology & Rare Disease Andy Schmeltz SVP, Commercial Strategy & Innovation December 12, 2022 Breakthroughs that change patients’ lives® 102
Slide 103: Sickle Cell Disease (SCD) is a Devastating Genetic Disorder
Inclacumab & GBT-601 Sickle Cell Disease (SCD) is a Devastating Genetic Disorder, Affecting Millions Worldwide, with a Significant Impact on QoL and Survival ~100K in the US and ~50K in EU1,2; over 4.5 million patients3 worldwide Frequent/prolonged hospitalizations disrupt daily life; Hemolysis & va
Slide 104: SCD is Driven by Hemoglobin Polymerization
Inclacumab & GBT-601 SCD is Driven by Hemoglobin Polymerization Sickle hemoglobin with no oxygen Too few VOCs and Hemolysis (clumped) RBCs, Anemia leads to Multi-Organ Dysfunction Oxygen Hemoglobin Sickled carrying oxygen cell Breakdown of RBCs, Hemolysis Blockage of Blood Vessels, Pain Crises, VOCs
Slide 105: SCD: Multiple Targets for Intervention
Inclacumab & GBT-601 SCD: Multiple Targets for Intervention Sickle hemoglobin with no oxygen Too few VOCs and Hemolysis (clumped) RBCs, Anemia leads to Multi-Organ Dysfunction Oxygen Hemoglobin Sickled carrying oxygen cell Breakdown of RBCs, Hemolysis Polymerization Blockage of Blood Vessels, HbF Mo
Slide 106: Treatment Approaches
Inclacumab & GBT-601 Treatment Approaches Standard Treatment & Prevention Include Prophylactic Antibiotics, Vaccination, Opiates, Erythrocyte Transfusion with Iron Chelation Hydroxyurea L-glutamine Crizanlizumab Oxbryta In vivo/Ex vivo Allogeneic Stem Cell Transplant Increases Improving RBC P-select
Slide 107: Inclacumab Can Potentially Address Chronic VOCs and Hospital Readmissions
Inclacumab & GBT-601 Inclacumab Can Potentially Address Chronic VOCs and Hospital Readmissions Current Approved VOC Therapy not Indicated to Reduce Hospital Readmission Impact of VOCs Opportunities for Platelet-Leukocyte Aggregation in SCD Patient4 Differentiation • Fully human IgG4 monoclonal PLA i
Slide 108: GBT-601 is Positioned to be a Potential Best-in-Class HbS Polymerization Inhibitor
Inclacumab & GBT-601 GBT-601 is Positioned to be a Potential Best-in-Class HbS Polymerization Inhibitor Mechanism of Action Preclinical Data Potential for: • A next-generation HbS • Increased Hemoglobin • Improved efficacy polymerization inhibitor; similar mechanism to Oxbryta – the first • Reduced
Slide 109: GBT-601: Potential Best-in-Class Polymerization Inhibitor
Inclacumab & GBT-601 GBT-601: Potential Best-in-Class Polymerization Inhibitor Improvements in Sickling, Hemolytic Anemia and Hb Occupancy in Phase 1* Phase 1, Reduced Hemolysis Increased Hb by >2g/dL Phase 1, Single dose → multiple ascending doses SCD Patients Treated with 100 mg GBT601 to reach a
Slide 110: GBT-601 Phase 1 ASH 2022 Data Show Meaningful Increases in Hematocrit and Hb Levels
Inclacumab & GBT-601 GBT-601 Phase 1 ASH 2022 Data Show Meaningful Increases in Hematocrit and Hb Levels Phase 1, Single 100 mg dose → multiple ascending doses to reach a % Hb occupancy >30% Hematocrit and Hb Levels After Multiple-Dose GBT-601 Treatment in Patients with SCD 40 Hematocrit Levels Hemo
Slide 111: SCD Clinical Development Plan
Inclacumab & GBT-601 SCD Clinical Development Plan Developing Potentially Differentiated Therapies for People with SCD, Phase 3 Studies Inclacumab Ongoing THRIVE Chronic Prevention Protocol N = 240 Primary Endpoint: VOC rate during 48-week treatment period THRIVE Chronic Prevention Protocol Potentia
Slide 112: Market Opportunity: Sickle Cell Disease Prophylaxis
Inclacumab & GBT-601 Market Opportunity: Sickle Cell Disease Prophylaxis Improved Therapies Anticipated to Increase Prophylaxis Treatment Rate by ~50% in the Coming Ten Years Treatment Rates for SCD Patients Over Time (Illustrative) 33% Patient Share 55% 67% Untreated US 67% 45% 33% Prophylaxis Trea
Slide 113: Commercial Potential for GBT-601 and Inclacumab
Inclacumab & GBT-601 Commercial Potential for GBT-601 and Inclacumab Opportunity for GBT-601 & Inclacumab to Potentially Reach >$3B in Combined Peak Year Sales Sickle Cell Disease 120K 2032 US total prevalence1 ~50–75% 2032 expected prophylaxis treatment rate (increasing from ~45% today)2 Inclacumab
Slide 114: In Brief: GBT-601 and Inclacumab Are Exciting New Potential Therapies for SCD
Inclacumab & GBT-601 In Brief: GBT-601 and Inclacumab Are Exciting New Potential Therapies for SCD GBT-601 – Potential to A Compelling Value Proposition Reduce RBC sickling and hemolysis 1 We believe GBT-601 is poised to be a foundational best-in-class oral therapy for all Meaningfully reduce VOCs p
Slide 115: mRNA Vaccine Developments
mRNA Vaccine Developments Working to Expand Pfizer's Leadership Annaliesa Anderson, PhD, FAAM SVP, Chief Scientific Officer Vaccine Research & Development Navin Katyal U.S. Commercial & Global Business Lead for mRNA Portfolio December 12, 2022 115
Slide 116: Enhancing and Expanding mRNA Vaccine Leadership
mRNA Enhancing and Expanding mRNA Vaccine Leadership Building on the Success of 4 Pivotal Vaccine Readouts in 2022 Pentavalent Meningococcal* RSV* Prevnar 20™** adolescent pediatric maternal and adult Pneumococcal 20-valent Conjugate Vaccine Select mRNA Programs Preclinical Phase 1 Phase 2 Phase 3 R
Slide 117: Disease Overview & Unmet Need: Traditional Flu Vaccine Timeline
mRNA Disease Overview & Unmet Need: Traditional Flu Vaccine Timeline Struggles to Meet Public Health Need mRNA Platform Shortens Timelines Which Could Enable a Quicker Response to Flu Evolution In the US, Elderly Account for Estimated 3–5M 140–710K Hospitalizations and ~90% $25B Severe Cases/Yr Glob
Slide 118: Low Seasonal Flu Vaccine Effectiveness is a Key Driver of Public Health Burden
mRNA Low Seasonal Flu Vaccine Effectiveness is a Key Driver of Public Health Burden Antigenic Drift and/or Egg-adapted Mutations Contribute to Variability 100 Low effectiveness due to antigenic drift 90 Low effectiveness due to egg-adapted mutations 80 Percent Effective 70 60 60 56 52 52 49 48 50 47
Slide 119: Three-Pronged Approach That Aims to Transform Flu Vaccine Industry
mRNA Three-Pronged Approach That Aims to Transform Flu Vaccine Industry Goals Improve Quadrivalent, Combine with Other Vaccines, and Broaden Coverage 1 2 3 B/Victoria A/H3N2 COVID Flu B/Yamagata A/H1N1 modRNA quadrivalent Increase Antigens (hemagglutinin) modRNA Quadrivalent Respiratory Combination
Slide 120: Minimal Interference Seen Pre-Clinically in Flu/COVID Combo
mRNA Minimal Interference Seen Pre-Clinically in Mice in 2 Flu/COVID Combo Compared to Standalone mRNA Vaccines COVID Vaccine Responses1 Flu Vaccine Responses1 4 A/H1N1 A/H3N2 B/Victoria B/Yamagata 4 50% Neutralization Titer (10X) 50% pVNT Titer (10x) 3 3 Wuhan 2 BA.4/5 2 LOD 1 1 Bivalent COVID Biva
Slide 121: Advancing mRNA Technology Through the Use of Self-Amplifying RNA (saRNA)
mRNA 3 Advancing mRNA Technology Through the Use of Self-Amplifying RNA (saRNA) modRNA LNP Formulation Potential Advantages of saRNA 5’ Hemagglutinin 3’ Cell Single Antigen Cell mRNA Entry • Increased duration of expression Nucleus • Lower dose levels saRNA • Improved tolerability Nucleus 5’ saRNA R
Slide 122: Traditional Flu Vaccines Do Not Contain Consistent Levels of Neuraminidase
mRNA 3 Traditional Flu Vaccines Do Not Contain Consistent Levels of Neuraminidase (NA) saRNA Enables Co-Expression of NA and May Provide an Opportunity to Express Additional Antigens Hemagglutination Inhibition Assay Hemagglutination Neuraminidase Neuraminidase Inhibition Assay Inhibition Assay Inih
Slide 123: Disease Overview & Unmet Need: Shingles (Herpes Zoster)
mRNA Disease Overview & Unmet Need: Shingles (Herpes Zoster) modRNA Vaccine Has the Potential to Meet the Significant Burden of Disease and Have Better Tolerability Globally, Each Year VZV is Responsible A modRNA Vaccine Has the Potential to Be Less for ~24M Shingles (Herpes Zoster) Reactogenic than
Slide 124: Pre-clinical Studies Highlight modRNA Efficacy for Shingles Vaccine Candidate
mRNA Pre-clinical Studies Highlight modRNA Efficacy and Potential for Highly Potent Shingles Vaccine Candidate CD4+ T cells CD8+ T cells 10 4 2.5 2.0 10 3 IgG (μg/ml) % of T cells 1.5 (p< 0.001) 10 2 ✱✱✱ 1.0 10 1 0.5 10 0 0.0 Shingrix modRNA Shingrix modRNA Shingrix modRNA 2 weeks post-dose 2 in mic
Slide 125: Pfizer is Uniquely Positioned to Deliver the Full Value of Innovative mRNA Vaccine Solutions
mRNA Pfizer is Uniquely Positioned to Deliver the Full Value of Innovative mRNA Vaccine Solutions on a Global Scale 1 2 3 4 Proven Global Leadership Broad Vaccines Industry Leading Speed Global Commercial in mRNA Vaccine Portfolio Across and Agility in Development Footprint and Commercialization Mod
Slide 126: mRNA Vaccines Market Opportunity and Commercial Potential
mRNA mRNA Vaccines Market Opportunity and Commercial Potential Expected to Achieve Substantial and Sustainable Revenues as We Transition Out of the Pandemic State 2020–22 2030 Pfizer internal expectations & goals A leading Influenza Vaccine COVID-19 + Influenza Shingles Vaccine2 COVID-19 Combination
Slide 127: In Brief: Pfizer is Prepared to Expand in mRNA Vaccines
mRNA In Brief: Pfizer is Prepared to Expand in mRNA Vaccines We Have Great Confidence in Our Future mRNA …with Compelling Value Propositions Across Vaccines Portfolio… Our mRNA Vaccines Pipeline • Promising mRNA vaccines pipeline • Influenza Vaccine – Potential for broader immune response, improved
Slide 128: Q&A High-Value Pipeline
Q&A High-Value Pipeline I< Pfizer
Slide 129: Near-Term Launches High-Value Pipeline Day
Near-Term Launches High-Value Pipeline Day David Denton Chief Financial Officer, Executive Vice President December 12, 2022 Breakthroughs that change patients’ lives ® 129
Slide 130: Fortifying our Long-Term Growth Plans
Closing Fortifying our Long-Term Growth Plans Illustrative* 2025-2030 Projections ~$20B4 Key drivers At least • INF-Beta $25B3 • GLP1 ~$17B2 Key drivers • TTI-622 • RSV • mRNA • Elranatamab • Ritlecitinib Key drivers • Talzenna+ Xtandi • Migraine Franchise • Oxbryta + GBT-601 • Etrasimod 2025 Baseli
Slide 131: New Launches / Co-promotions and Potential Product Launches
Introduction New Launches / Co-promotions and Potential Product Launches1 Product Candidate Anticipated Indication Expected Launch New Molecular Entity (NME) Launches Ngenla (Ex-US) Growth Hormone Deficiency 2022 Ritlecitinib Alopecia Areata 2023 Elranatamab Triple Class Relapsed or Refractory (Resi
Slide 132: Expected Revenue Growth in 2023
Closing +7-9% Expected Revenue Growth in 2023 (Excluding COVID-19 Products and Excluding the Impact of Foreign Exchange) To help ensure successful launches, we plan to significantly increase investment in our commercial and R&D organizations in 2023. Near-Term Launches High-Value Pipeline Day | Clos
Slide 133: Appendix
Appendix I< Pfizer
Slide 134: CIBINQO: Strongly Positioned to Help Address the Unmet Need in AD
Other Launches CIBINQO: Strongly Positioned to Help Address the Unmet Need in AD, With Significant Growth Potential Significant Unmet Need and Growth Raising The Bar in the Management Promising Early Launch Signals Potential in Atopic Dermatitis of Moderate to Severe AD High Disease Prevalence • Sig
Slide 135: BRAFTOVI / MEKTOVI Continues to Advance with Additional Indications
Other Launches BRAFTOVI / MEKTOVI Continues to Advance with Additional Indications, as We Plan for Potential Launch in BRAF-Mutant mNSCLC* in 2023 Approvals & Expected Readouts STARBOARD Approved Indications 1L BRAF-mutant Lifecycle / Expected Planned 2023 Launch* Metastatic Melanoma Readout PHAROS
Slide 136: PCV20 Potential Pediatric Indication
Other Launches PCV20 Potential Pediatric Indication: Building on Pfizer’s 20+ Year Legacy as a Leader in Pediatric Pneumococcal Conjugate Vaccines Broadest IPD Coverage Significant Unmet Need Poised to Drive Rapid of any PCV Positive Phase 3 Results Remains PCV20 Pediatric candidate will only help p
Slide 137: Pfizer's Pentavalent Meningococcal Vaccine Candidate (MenABCWY)
Other Launches Pfizer’s Pentavalent Meningococcal Vaccine Candidate* (MenABCWY) Provides an Opportunity to Strengthen Our Position as a Global Leader in Protection Invasive Meningococcal Disease Public Health Need: Protection Penta Value Proposition: Potential Pfizer Was First to (IMD) is an Uncommo
Slide 138: Pfizer's End-to-End Capabilities Position Us in COVID-19 Vaccines
Other Launches Pfizer’s End-to-End Capabilities Position Us to be a Clear Market Leader, with our collaboration partner BioNTech, in COVID-19 Vaccines as the Virus Continues to Evolve Development & Manufacturing Scale Proven Commercial Regulatory Agility & Global Reach Leadership ~60 1st >225m >40 #
Slide 139: Glossary
Glossary I< Pfizer
Slide 140: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition 1L First Line, typically used in oncology. Refers to the first treatment regimen that a newly diagnosed patient receives. 5-ASA 5-Aminosalicylates, oral therapies used to treat diseases such as UC and Crohn’s
Slide 141: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition ASH American Society of Hematology AT Advanced Treatment, in the context used here refers to immunological therapies that come after older systemic therapies like steroids or broadly immunosuppressive agents.
Slide 142: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition CR Complete Response, generally means disappearance of all signs of cancer in response to treatment. CRS Cytokine Release Syndrome, a side effect of immunotherapy due to the release of cytokines into the blood
Slide 143: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition EMD Extramedullary Disease, which occurs when myeloma cells form tumors outside the bone marrow in the soft tissues or organs of the body. FPG Fasting plasma glucose, a measure of blood sugar in the fasted sta
Slide 144: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition HRR Homologous Recombination Repair Describes a process in a cell in which a group of proteins work together to repair DNA damage. Changes in the homologous recombination repair pathway that result in the inab
Slide 145: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition MMS Modified Mayo Score, a standardized measure used in clinical trials for UC. modRNA Modified mRNA refers to mRNA which has added or altered components not normally present in native human mRNA. These compon
Slide 146: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition ORR Objective Response Rate, refers to percentage of people in a study or treatment group who have a partial or complete response to treatment in a certain period of time. OS Overall Survival the length of tim
Slide 147: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition PSA Prostrate Specific Antigen a protein made by the prostate gland and found in the blood. PSA blood levels may be higher than normal in men who have prostate cancer. PtGA Patient Global Assessment, a quantit
Slide 148: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition RSV Respiratory Syncytial Virus, an extremely common seasonal(fall/winter) respiratory virus. Most of the burden of the disease (hospitalization and potentially death) is borne by young infants (especially < 6
Slide 149: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition Shingles Shingles is a recurrent manifestation of an earlier infection with chickenpox (aka varicella zoster virus, VZV, or herpes zoster virus, HZV). Once the immune system fights the acute chicken pox infect
Slide 150: Glossary of Medical and Scientific Terms
Glossary Glossary of Medical and Scientific Terms Acronym / Abbreviation / Term Definition UC Ulcerative Colitis, an autoimmune condition impacting the colon (large intestine). VOCs Vaso-occlusive crises, painful episodes caused by red blood cells sickling and blocking blood vessels in patients with
Slide 151: Key LOE Products 2026 - 2030
Key LOE Products 2026 - 2030 151
Slide 152: Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines
LOEs Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines from 2025-2030 2021 WW 2021 U.S. 2021 Dev. EU Year of Year of Revenues Revenues Revenues Expected U.S. Expected EU Product ($ millions) ($ millions) ($ millions) LOE LOE Eliquis $5,970 $3,160 $1,520 2026* 2026 Inlyta $1,
Slide 153: Thank You
Thank You Near-Term Launches High-Value Pipeline Day 153